Of particular importance, patient-derived T cells treated with IL-27 displayed a higher cytotoxic ability toward leukemic cells than their untreated counterparts; highlighting the potential of this cytokine to reactivate anti-tumor immunity in CLL patients. This evidence concerns the gene IL27 and B-cell chronic lymphocytic leukemia.